Search

Your search keyword '"Van Hemelrijck, Mieke"' showing total 25 results
Start Over Author "Van Hemelrijck, Mieke" Journal european urology
25 results on '"Van Hemelrijck, Mieke"'

1. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data

Author

Gandaglia, Giorgio, Pellegrino, Francesco, Golozar, Asieh, De Meulder, Bertrand, Abbott, Thomas, Achtman, Ariel, Imran Omar, Muhammad, Alshammari, Thamir, Areia, Carlos, Asiimwe, Alex, Beyer, Katharina, Bjartell, Anders, Campi, Riccardo, Cornford, Philip, Falconer, Thomas, Feng, Qi, Gong, Mengchun, Herrera, Ronald, Hughes, Nigel, Hulsen, Tim, Kinnaird, Adam, Lai, Lana Y.H., Maresca, Gianluca, Mottet, Nicolas, Oja, Marek, Prinsen, Peter, Reich, Christian, Remmers, Sebastiaan, Roobol, Monique J., Sakalis, Vasileios, Seager, Sarah, Smith, Emma J., Snijder, Robert, Steinbeisser, Carl, Thurin, Nicolas H., Hijazy, Ayman, van Bochove, Kees, Van den Bergh, Roderick C.N., Van Hemelrijck, Mieke, Willemse, Peter-Paul, Williams, Andrew E., Zounemat Kermani, Nazanin, Evans-Axelsson, Susan, Briganti, Alberto, and N'Dow, James

Published
2024
Full Text
View/download PDF

2. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

Author

Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Zhang, Liying, Santa Olalla, Aida, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, La Pointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, and Bruinsma, Sophie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Prevention, Urologic Diseases, Cancer, Good Health and Well Being, Aged, Asia, Australia, Biopsy, Cause of Death, Clinical Decision-Making, Databases, Factual, Disease Progression, Early Detection of Cancer, Europe, Humans, Kallikreins, Male, Middle Aged, North America, Patient Dropouts, Predictive Value of Tests, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Risk Factors, Time Factors, Watchful Waiting, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for

Published
2019

3. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium

Author

Beyer, Katharina, Moris, Lisa, Lardas, Michael, Omar, Muhammad Imran, Healey, Jemma, Tripathee, Sheela, Gandaglia, Giorgio, Venderbos, Lionne D.F., Vradi, Eleni, van den Broeck, Thomas, Willemse, Peter-Paul, Antunes-Lopes, Tiago, Pacheco-Figueiredo, Luis, Monagas, Serenella, Esperto, Francesco, Flaherty, Stephen, Devecseri, Zsuzsanna, Lam, Thomas B.L., Williamson, Paula R., Heer, Rakesh, Smith, Emma J., Asiimwe, Alex, Huber, Johannes, Roobol, Monique J., Zong, Jihong, Mason, Malcolm, Cornford, Philip, Mottet, Nicolas, MacLennan, Sara J., N'Dow, James, Briganti, Alberto, MacLennan, Steven, and Van Hemelrijck, Mieke

Published
2022
Full Text
View/download PDF

4. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial

Author

Baig, Umair, Aya, Haleema, Husnain Iqbal, Mohammed, Kum, Francesca, Bultitude, Matthew, Glass, Jonathan, Khan, Azhar, Makanjuola, Jonathan, McCabe, John E., Samsuddin, Azi, McIlhenny, Craig, Brewin, James, Kulkarni, Shashank, Khwaja, Sikandar, Islam, Waliul, Marsh, Howard, Bhat, Taher, Thomas, Benjamin, Cutress, Mark, Housami, Fadi, Nedas, Timothy, Bates, Timothy, Mukherjee, Rono, Graham, Stuart, Bordenave, Matthieu, Coker, Charles, Ahmed, Shwan, Symes, Andrew, Calvert, Robert, Lynch, Ciaran, Long, Ronan, Patterson, Jacob M., Rukin, Nicholas J., Khan, Shahid A., Dasgupta, Ranan, Brown, Stephen, Grey, Ben, Mahmalji, Waseem, Lam, Wayne, Scheitlin, Walter, Saelzler, Norbert, Fiedler, Marcel, Ishikawa, Shuhei, Sasaki, Yoshihiro, Sazawa, Ataru, Shinno, Yuichiro, Mochizuki, Tango, Peter Jessen, Jan, Steiner, Roland, Wendt-Nordahl, Gunnar, Atassi, Nabil, Kohns, Heiko, Cox, Ashley, Rendon, Ricardo, Lawen, Joseph, Bailly, Greg, Marsh, Trevor, Aydın, Abdullatif, Ahmed, Kamran, Abe, Takashige, Raison, Nicholas, Van Hemelrijck, Mieke, Garmo, Hans, Ahmed, Hashim U., Mukhtar, Furhan, Al-Jabir, Ahmed, Brunckhorst, Oliver, Shinohara, Nobuo, Zhu, Wei, Zeng, Guohua, Sfakianos, John P., Gupta, Mantu, Tewari, Ashutosh, Gözen, Ali Serdar, Rassweiler, Jens, Skolarikos, Andreas, Kunit, Thomas, Knoll, Thomas, Moltzahn, Felix, Thalmann, George N., Lantz Powers, Andrea G., Chew, Ben H., Sarica, Kemal, Shamim Khan, Muhammad, and Dasgupta, Prokar

Published
2022
Full Text
View/download PDF

5. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data

Author

Gandaglia, Giorgio, primary, Pellegrino, Francesco, additional, Golozar, Asieh, additional, De Meulder, Bertrand, additional, Abbott, Thomas, additional, Achtman, Ariel, additional, Imran Omar, Muhammad, additional, Alshammari, Thamir, additional, Areia, Carlos, additional, Asiimwe, Alex, additional, Beyer, Katharina, additional, Bjartell, Anders, additional, Campi, Riccardo, additional, Cornford, Philip, additional, Falconer, Thomas, additional, Feng, Qi, additional, Gong, Mengchun, additional, Herrera, Ronald, additional, Hughes, Nigel, additional, Hulsen, Tim, additional, Kinnaird, Adam, additional, Lai, Lana Y.H., additional, Maresca, Gianluca, additional, Mottet, Nicolas, additional, Oja, Marek, additional, Prinsen, Peter, additional, Reich, Christian, additional, Remmers, Sebastiaan, additional, Roobol, Monique J., additional, Sakalis, Vasileios, additional, Seager, Sarah, additional, Smith, Emma J., additional, Snijder, Robert, additional, Steinbeisser, Carl, additional, Thurin, Nicolas H., additional, Hijazy, Ayman, additional, van Bochove, Kees, additional, Van den Bergh, Roderick C.N., additional, Van Hemelrijck, Mieke, additional, Willemse, Peter-Paul, additional, Williams, Andrew E., additional, Zounemat Kermani, Nazanin, additional, Evans-Axelsson, Susan, additional, Briganti, Alberto, additional, and N'Dow, James, additional

Published
2023
Full Text
View/download PDF

6. Erratum to “Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial” [Eur Urol 2022;81:385–393]

Author

Aydın, Abdullatif, primary, Ahmed, Kamran, additional, Abe, Takashige, additional, Raison, Nicholas, additional, Van Hemelrijck, Mieke, additional, Garmo, Hans, additional, Ahmed, Hashim U., additional, Mukhtar, Furhan, additional, Al-Jabir, Ahmed, additional, Brunckhorst, Oliver, additional, Shinohara, Nobuo, additional, Zhu, Wei, additional, Zeng, Guohua, additional, Sfakianos, John P., additional, Gupta, Mantu, additional, Tewari, Ashutosh, additional, Serdar Gözen, Ali, additional, Rassweiler, Jens, additional, Skolarikos, Andreas, additional, Kunit, Thomas, additional, Knoll, Thomas, additional, Moltzahn, Felix, additional, Thalmann, George N., additional, Lantz Powers, Andrea G., additional, Chew, Ben H., additional, Sarica, Kemal, additional, Shamim Khan, Muhammad, additional, Dasgupta, Prokar, additional, Baig, Umair, additional, Aya, Haleema, additional, Husnain Iqbal, Mohammed, additional, Kum, Francesca, additional, Bultitude, Matthew, additional, Glass, Jonathan, additional, Khan, Azhar, additional, Makanjuola, Jonathan, additional, McCabe, John E., additional, Samsuddin, Azi, additional, McIlhenny, Craig, additional, Brewin, James, additional, Kulkarni, Shashank, additional, Khwaja, Sikandar, additional, Islam, Waliul, additional, Marsh, Howard, additional, Bhat, Taher, additional, Thomas, Benjamin, additional, Cutress, Mark, additional, Housami, Fadi, additional, Nedas, Timothy, additional, Bates, Timothy, additional, Mukherjee, Rono, additional, Graham, Stuart, additional, Bordenave, Matthieu, additional, Coker, Charles, additional, Ahmed, Shwan, additional, Symes, Andrew, additional, Calvert, Robert, additional, Lynch, Ciaran, additional, Long, Ronan, additional, Patterson, Jacob M., additional, Rukin, Nicholas J., additional, Khan, Shahid A., additional, Dasgupta, Ranan, additional, Brown, Stephen, additional, Grey, Ben, additional, Mahmalji, Waseem, additional, Lam, Wayne, additional, Scheitlin, Walter, additional, Saelzler, Norbert, additional, Fiedler, Marcel, additional, Ishikawa, Shuhei, additional, Sasaki, Yoshihiro, additional, Sazawa, Ataru, additional, Shinno, Yuichiro, additional, Mochizuki, Tango, additional, Peter Jessen, Jan, additional, Steiner, Roland, additional, Wendt-Nordahl, Gunnar, additional, Atassi, Nabil, additional, Kohns, Heiko, additional, Cox, Ashley, additional, Rendon, Ricardo, additional, Lawen, Joseph, additional, Bailly, Greg, additional, and Marsh, Trevor, additional

Published
2022
Full Text
View/download PDF

7. Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen’s Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503–14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates

Author

Beyer, Katharina, primary, MacLennan, Steven, additional, and Van Hemelrijck, Mieke, additional

Published
2022
Full Text
View/download PDF

8. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial

Author

Aydın, Abdullatif, primary, Ahmed, Kamran, additional, Abe, Takashige, additional, Raison, Nicholas, additional, Van Hemelrijck, Mieke, additional, Garmo, Hans, additional, Ahmed, Hashim U., additional, Mukhtar, Furhan, additional, Al-Jabir, Ahmed, additional, Brunckhorst, Oliver, additional, Shinohara, Nobuo, additional, Zhu, Wei, additional, Zeng, Guohua, additional, Sfakianos, John P., additional, Gupta, Mantu, additional, Tewari, Ashutosh, additional, Gözen, Ali Serdar, additional, Rassweiler, Jens, additional, Skolarikos, Andreas, additional, Kunit, Thomas, additional, Knoll, Thomas, additional, Moltzahn, Felix, additional, Thalmann, George N., additional, Lantz Powers, Andrea G., additional, Chew, Ben H., additional, Sarica, Kemal, additional, Shamim Khan, Muhammad, additional, Dasgupta, Prokar, additional, Baig, Umair, additional, Aya, Haleema, additional, Husnain Iqbal, Mohammed, additional, Kum, Francesca, additional, Bultitude, Matthew, additional, Glass, Jonathan, additional, Khan, Azhar, additional, Makanjuola, Jonathan, additional, McCabe, John E., additional, Samsuddin, Azi, additional, McIlhenny, Craig, additional, Brewin, James, additional, Kulkarni, Shashank, additional, Khwaja, Sikandar, additional, Islam, Waliul, additional, Marsh, Howard, additional, Bhat, Taher, additional, Thomas, Benjamin, additional, Cutress, Mark, additional, Housami, Fadi, additional, Nedas, Timothy, additional, Bates, Timothy, additional, Mukherjee, Rono, additional, Graham, Stuart, additional, Bordenave, Matthieu, additional, Coker, Charles, additional, Ahmed, Shwan, additional, Symes, Andrew, additional, Calvert, Robert, additional, Lynch, Ciaran, additional, Long, Ronan, additional, Patterson, Jacob M., additional, Rukin, Nicholas J., additional, Khan, Shahid A., additional, Dasgupta, Ranan, additional, Brown, Stephen, additional, Grey, Ben, additional, Mahmalji, Waseem, additional, Lam, Wayne, additional, Scheitlin, Walter, additional, Saelzler, Norbert, additional, Fiedler, Marcel, additional, Ishikawa, Shuhei, additional, Sasaki, Yoshihiro, additional, Sazawa, Ataru, additional, Shinno, Yuichiro, additional, Mochizuki, Tango, additional, Peter Jessen, Jan, additional, Steiner, Roland, additional, Wendt-Nordahl, Gunnar, additional, Atassi, Nabil, additional, Kohns, Heiko, additional, Cox, Ashley, additional, Rendon, Ricardo, additional, Lawen, Joseph, additional, Bailly, Greg, additional, and Marsh, Trevor, additional

Published
2022
Full Text
View/download PDF

10. Erratum to “Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial” [Eur Urol 2022;81:385–393]

Author

Baig, Umair, Aya, Haleema, Husnain Iqbal, Mohammed, Kum, Francesca, Bultitude, Matthew, Glass, Jonathan, Khan, Azhar, Makanjuola, Jonathan, McCabe, John E., Samsuddin, Azi, McIlhenny, Craig, Brewin, James, Kulkarni, Shashank, Khwaja, Sikandar, Islam, Waliul, Marsh, Howard, Bhat, Taher, Thomas, Benjamin, Cutress, Mark, Housami, Fadi, Nedas, Timothy, Bates, Timothy, Mukherjee, Rono, Graham, Stuart, Bordenave, Matthieu, Coker, Charles, Ahmed, Shwan, Symes, Andrew, Calvert, Robert, Lynch, Ciaran, Long, Ronan, Patterson, Jacob M., Rukin, Nicholas J., Khan, Shahid A., Dasgupta, Ranan, Brown, Stephen, Grey, Ben, Mahmalji, Waseem, Lam, Wayne, Scheitlin, Walter, Saelzler, Norbert, Fiedler, Marcel, Ishikawa, Shuhei, Sasaki, Yoshihiro, Sazawa, Ataru, Shinno, Yuichiro, Mochizuki, Tango, Peter Jessen, Jan, Steiner, Roland, Wendt-Nordahl, Gunnar, Atassi, Nabil, Kohns, Heiko, Cox, Ashley, Rendon, Ricardo, Lawen, Joseph, Bailly, Greg, Marsh, Trevor, Aydın, Abdullatif, Ahmed, Kamran, Abe, Takashige, Raison, Nicholas, Van Hemelrijck, Mieke, Garmo, Hans, Ahmed, Hashim U., Mukhtar, Furhan, Al-Jabir, Ahmed, Brunckhorst, Oliver, Shinohara, Nobuo, Zhu, Wei, Zeng, Guohua, Sfakianos, John P., Gupta, Mantu, Tewari, Ashutosh, Serdar Gözen, Ali, Rassweiler, Jens, Skolarikos, Andreas, Kunit, Thomas, Knoll, Thomas, Moltzahn, Felix, Thalmann, George N., Lantz Powers, Andrea G., Chew, Ben H., Sarica, Kemal, Shamim Khan, Muhammad, and Dasgupta, Prokar

Published
2022
Full Text
View/download PDF

12. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts

Author

Drost, Frank-Jan H., primary, Nieboer, Daan, additional, Morgan, Todd M., additional, Carroll, Peter R., additional, Roobol, Monique J., additional, Trock, Bruce, additional, Ehdaie, Behfar, additional, Carroll, Peter, additional, Filson, Christopher, additional, Kim, Jeri, additional, Logothetis, Christopher, additional, Morgan, Todd, additional, Klotz, Laurence, additional, Pickles, Tom, additional, Hyndman, Eric, additional, Moore, Caroline M., additional, Gnanapragasam, Vincent, additional, Van Hemelrijck, Mieke, additional, Dasgupta, Prokar, additional, Bangma, Chris, additional, Roobol, Monique, additional, Villers, Arnauld, additional, Rannikko, Antti, additional, Perry, Antoinette, additional, Hugosson, Jonas, additional, Rubio-Briones, Jose, additional, Bjartell, Anders, additional, Hefermehl, Lukas, additional, Shiong, Lee Lui, additional, Frydenberg, Mark, additional, Kakehi, Yoshiyuki, additional, Chung, Byung Ha, additional, van der Kwast, Theo, additional, van der Linden, Wim, additional, Hulsen, Tim, additional, de Jonge, Cees, additional, Kattan, Mike, additional, Xinge, Ji, additional, Muir, Kenneth, additional, Lophatananon, Artitaya, additional, Fahey, Michael, additional, Steyerberg, Ewout, additional, Zhang, Liying, additional, Beckmann, Kerri, additional, Denton, Brian, additional, Hayen, Andrew, additional, Boutros, Paul, additional, Guo, Wei, additional, Benfante, Nicole, additional, Cowan, Janet, additional, Patil, Dattatraya, additional, Tolosa, Emily, additional, Kim, Tae-Kyung, additional, Mamedov, Alexandre, additional, LaPointe, Vincent, additional, Crump, Trafford, additional, Kimberly-Duffell, Jenna, additional, Santaolalla, Aida, additional, Olivier, Jonathan, additional, Rancati, Tiziana, additional, Ahlgren, Helén, additional, Mascarós, Juanma, additional, Löfgren, Annica, additional, Lehmann, Kurt, additional, Han Lin, Catherine, additional, Hirama, Hiromi, additional, Suk Lee, Kwang, additional, Jenster, Guido, additional, Auvinen, Anssi, additional, Haider, Masoom, additional, van Bochove, Kees, additional, Carter, Ballentine, additional, Gledhill, Sam, additional, Buzza, Mark, additional, Bruinsma, Sophie, additional, and Helleman, Jozien, additional

Published
2019
Full Text
View/download PDF

13. Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260–1

Author

Bessa, Agustina, primary, Maclennan, Steven, additional, Enting, Deborah, additional, Bryan, Richard, additional, Häggström, Christel, additional, and Van Hemelrijck, Mieke, additional

Published
2019
Full Text
View/download PDF

14. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method

Author

Bessa, Agustina, primary, Maclennan, Steven, additional, Enting, Deborah, additional, Bryan, Richard, additional, Josephs, Debra, additional, Hughes, Simon, additional, Amery, Suzanne, additional, Khan, Muhammad Shamim, additional, Malde, Sachin, additional, Nair, Rajesh, additional, Cahill, Fidelma, additional, Wylie, Harriet, additional, Thurairaja, Ramesh, additional, Chatterton, Kathryn, additional, Kinsella, Netty, additional, Häggström, Christel, additional, and Van Hemelrijck, Mieke, additional

Published
2019
Full Text
View/download PDF

15. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer

Author

Beckmann, Kerri, primary, Garmo, Hans, additional, Adolfsson, Jan, additional, Bosco, Cecilia, additional, Johansson, Eva, additional, Robinson, David, additional, Holmberg, Lars, additional, Stattin, Par, additional, and Van Hemelrijck, Mieke, additional

Published
2019
Full Text
View/download PDF

24. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden

Author

Van Hemelrijck, Mieke, Garmo, Hans, Holmberg, Lars, Stattin, Pär, and Adolfsson, Jan

Subjects
*DIAGNOSIS, *PROSTATE cancer, *BONE fractures, *CARDIOVASCULAR diseases, *THROMBOEMBOLISM, *DISEASE management, *CONFIDENCE intervals, *MULTIVARIATE analysis
Abstract

Abstract: Background: To date, adverse events of prostate cancer (PCa) treatment have only been studied as a single event, and little is known about the risk of subsequent adverse events. Objective: We assessed the frequency of multiple events (fractures, stroke, heart disease [HD], and thromboembolic disease [TED]) following PCa diagnosis. Design, setting, and participants: PCBaSe Sweden is based on the National Prostate Cancer Register (NPCR) that covers >96% of incident PCa cases in Sweden. Measurements: We evaluated the number of events (fractures, stroke, HD, and TED) leading to hospitalisation recorded in the National Hospital Discharge Registry after PCa diagnosis and conducted multivariate age-adjusted Cox proportional hazards regression to estimate the risk of developing multiple events. Results and limitations: Between 1997 and 2007, 30 642 men received primary endocrine treatment, 26 432 curative treatment, and 19 526 surveillance: 75% had no event during follow-up, 17% had one event, and 9% had more than one event. The incidence of any event was 102 in 1000 person-years. Men who already had experienced an event, particularly HD, before or after the date of PCa diagnosis were more likely to have multiple events afterwards. For example, the hazard ratio of developing a third event for those with two or more events of HD before PCa diagnosis was 1.40 (95% confidence interval, 1.28–1.52) compared with those with no events of HD before PCa diagnosis. Events treated without hospitalisation were not included, so the number of adverse events is possibly underestimated. Conclusions: A third of PCa patients with an adverse event after treatment subsequently experienced another adverse event, but apart from history of HD or stroke before PCa diagnosis, no specific characteristics were found for these men. Thus PCa management needs to take into account the risk of adverse events in all PCa patients, especially those with a history of adverse events before PCa diagnosis. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

25. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer

Author

Hans Garmo, Kerri Beckmann, Mieke Van Hemelrijck, Lars Holmberg, Cecilia Bosco, Jan Adolfsson, Pär Stattin, David Robinson, Eva Johansson, Beckmann, Kerri, Garmo, Hans, Adolfsson, Jan, Bosco, Cecilia, Johansson, Eva, Robinson, David, Holmberg, Lars, Stattin, Par, and Van Hemelrijck, Mieke

Subjects
Oncology, Male, endocrine system, medicine.medical_specialty, Time Factors, Antineoplastic Agents, Hormonal, Databases, Factual, medicine.drug_class, Antiandrogens, Urology, 030232 urology & nephrology, androgen deprivation therapy, Gonadotropin-releasing hormone, Comorbidity, urologic and male genital diseases, Antiandrogen, Risk Assessment, Androgen deprivation therapy, Gonadotropin-Releasing Hormone, 03 medical and health sciences, Prostate cancer, gonadotropin-releasing hormone agonists, 0302 clinical medicine, Risk Factors, Internal medicine, Medicine, Humans, Registries, Adverse effect, Aged, Aged, 80 and over, Sweden, business.industry, fungi, Prostatic Neoplasms, antiandrogen monotherapy, Androgen Antagonists, prostate cancer, Androgen, medicine.disease, comorbidity, Treatment Outcome, 030220 oncology & carcinogenesis, business, hormones, hormone substitutes, and hormone antagonists, Hormone
Abstract

Background: Some studies suggest that gonadotropin-releasing hormone (GnRH) agonists are associated with higher risk of adverse events than antiandrogens (AAs) monotherapy. However, it has been unclear whether this is due to indication bias. Objective: To investigate rates of change in comorbidity for men on GnRH agonists versus AA monotherapy in a population-based register study. Design, setting, and participants: Men with advanced nonmetastatic prostate cancer (PCa) who received primary AA (n = 2078) or GnRH agonists (n = 4878) and age- and area-matched PCa-free men were selected from Prostate Cancer Database Sweden 3.0. Increases in comorbidity were measured using the Charlson Comorbidity Index (CCI), from 5 yr before through to 5 yr after starting androgen deprivation therapy (ADT). Outcome measures and statistical methods: Multivariable linear regression was used to determine differences in excess rate of CCI change before and after ADT initiation. Risk of any incremental change in CCI following ADT was assessed using multivariable Cox regression analyses. Results and limitations: Men on GnRH agonists experienced a greater difference in excess rate of CCI change after starting ADT than men on AA monotherapy (5.6% per yr, p < 0.001). Risk of any new CCI change after ADT was greater for GnRH agonists than for AA (hazard ratio, 1.32; 95% confidence interval, 1.20–1.44). Conclusions: Impact on comorbidity was lower for men on AA monotherapy than for men on GnRH agonists. Our results should be confirmed through randomised trials of effectiveness and adverse effects, comparing AA monotherapy and GnRH agonists in men with advanced nonmetastatic PCa who are unsuitable for curative treatment. Patient summary: Hormone therapies for advanced prostate cancer can increase the risk of other diseases (eg, heart disease, diabetes). This study compared two common forms of hormone therapy and found that the risk of another serious disease was higher for those on gonadotropin-releasing hormone agonists than for those on antiandrogen monotherapy. The increase in overall comorbidity following androgen androgen deprivation therapy for advanced prostate cancer was significantly higher for gonadotrophin gonadotrophin-releasing hormone agonists than for anti-androgen (AA) monotherapy. More consideration should be given to AA monotherapy as an alternative first-line therapy. Refereed/Peer-reviewed

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results